Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cancer research

Showing results (921-930 of 45,106) with videos related to

Pageof 4,511
Sort By:
Cancer Research|April 23, 2011
LIN28B promotes colon cancer progression and metastasisCatrina E King, Miriam Cuatrecasas, Antoni Castells, et al.
Cancer Research|April 23, 2011
Chronic inflammatory IFN-γ signaling suppresses hepatocarcinogenesis in mice by sensitizing hepatocytes for apoptosisStefan Lüth, Jörg Schrader, Stefan Zander, et al.
Cancer Research|July 7, 2011
YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growthAbbas Fotovati, Samah Abu-Ali, Pei-Shan Wang, et al.
Cancer Research|July 26, 2011
Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer modelDebbie Liao, Ze Liu, Wolfgang J Wrasidlo, et al.
Cancer Research|July 29, 2011
The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancerAtsushi Uesugi, Ken-Ichi Kozaki, Tomohiko Tsuruta, et al.
Cancer Research|June 29, 2011
Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinomaSophia Platonova, Julien Cherfils-Vicini, Diane Damotte, et al.
Cancer Research|June 29, 2011
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapyTihui Fu, Qiuming He, Padmanee Sharma
Cancer Research|June 24, 2011
Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR toleranceCarole Bourquin, Christian Hotz, Daniel Noerenberg, et al.
Cancer Research|June 24, 2011
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patientsRalph Tiedt, Elisa Degenkolbe, Pascal Furet, et al.
Cancer Research|October 15, 1990
Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cellsR Kopp, A Pfeiffer
Pageof 4,511

Showing results (921-930 of 45,106) with videos related to

Sort By:
Pageof 4,511
Cancer Research|April 23, 2011
LIN28B promotes colon cancer progression and metastasisCatrina E King, Miriam Cuatrecasas, Antoni Castells, et al.
Cancer Research|April 23, 2011
Chronic inflammatory IFN-γ signaling suppresses hepatocarcinogenesis in mice by sensitizing hepatocytes for apoptosisStefan Lüth, Jörg Schrader, Stefan Zander, et al.
Cancer Research|July 7, 2011
YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growthAbbas Fotovati, Samah Abu-Ali, Pei-Shan Wang, et al.
Cancer Research|July 26, 2011
Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer modelDebbie Liao, Ze Liu, Wolfgang J Wrasidlo, et al.
Cancer Research|July 29, 2011
The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancerAtsushi Uesugi, Ken-Ichi Kozaki, Tomohiko Tsuruta, et al.
Cancer Research|June 29, 2011
Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinomaSophia Platonova, Julien Cherfils-Vicini, Diane Damotte, et al.
Cancer Research|June 29, 2011
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapyTihui Fu, Qiuming He, Padmanee Sharma
Cancer Research|June 24, 2011
Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR toleranceCarole Bourquin, Christian Hotz, Daniel Noerenberg, et al.
Cancer Research|June 24, 2011
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patientsRalph Tiedt, Elisa Degenkolbe, Pascal Furet, et al.
Cancer Research|October 15, 1990
Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cellsR Kopp, A Pfeiffer
Pageof 4,511